Table 1.
Causes of anti-HIV first-line therapy discontinuation in the study population (n=1,096)
| Type | Tot | Strata | n | % Over strata | % Over total |
|---|---|---|---|---|---|
| Adverse events (toxicity/allergy) |
302 (1 death) |
Gastrointestinal |
86 |
28.5% |
7.8% |
| |
|
Hypersensitivity |
28 |
9.3% |
2.6% |
| |
|
Central nervous system |
18 |
6.0% |
1.6% |
| |
|
Hepatic |
14 |
4.6% |
1.3% |
| |
|
Metabolic (glucose or lipid metabolism, lipodystrophy) |
34 |
11.3% |
3.1% |
| |
|
Renal |
13 |
4.3% |
1.2% |
| |
|
Hematologic |
40 |
13.2% |
3.6% |
| |
|
Other |
69 |
22.8% |
6.3% |
| Other causes |
618 |
Simplification |
252 |
40.8% |
23.0% |
| |
|
Patient’s choice |
93 |
15.0% |
8.5% |
| |
|
Failure |
86 |
13.9% |
7.8% |
| |
|
Regimen intensification |
59 |
9.5% |
5.4% |
| |
|
Genotype-guided switch |
20 |
3.2% |
1.8% |
| |
|
Low adherence |
19 |
3.1% |
1.7% |
| |
|
End of pregnancy |
16 |
2.6% |
1.5% |
| |
|
Structured interruption |
13 |
2.1% |
1.2% |
| |
|
Enrolment in a new prospective study |
13 |
2.1% |
1.2% |
| |
|
Pregnancy |
12 |
1.9% |
1.1% |
| |
|
Other |
35 |
5.7% |
3.2% |
| Non-discontinued | 176 (6 deaths) | N/A | 176 | 100% | 16.1% |